Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and high relapse rates. The incorporation of immune checkpoint inhibitors (ICIs), particularly anti–PD-1/PD-L1 agents, into…
Tumor-Specific MHC-II Predicts Immunotherapy Response in Triple-Negative Breast Cancer
